Chris Kallos, CFA, is a healthcare and biotech equities analyst who has been active since 1998 and has extensive experience in both Australian and US stocks. He has covered small, medium and large cap stocks for a range of research houses in Australia, the United Kingdom and the United States. Chris holds a Bachelor of Pharmacy (Sydney), an MBA from the AGSM (UNSW), and a Masters of Applied Finance (Macquarie). He is a CFA charterholder and graduate of the Australian Institute of Company Directors. Chris Kallos is an authorised representative of Bridge Investment Research Pty Ltd, which is an authorised representative of MST Financial.